GlaxoSmithKline (NYSE:GSK) will present 11 abstracts on Blenrep (belantamab mafodotin blmf) at the American Society of Hematology (ASH) Annual Meeting and Exposition on December 11–14. Presentations will include new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial program and two collaborative studies focused on Blenrep.
The drug won FDA approval on August 5, 2020, for adults with relapsed or refractory multiple myeloma who have received at least four prior therapies.
Featured presentations at ASH includes poster #2738, which will describe outcomes of regimen of belantamab mafodotin with the chemotherapies bortezomib and lenalidomide plus the steroid dexamethasone in transplant-ineligible patients with recently diagnosed multiple myeloma.
Another presentation will detail results from the BelaRd trial (poster #2736) from Hellenic Society of Hematology in collaboration with GSK exploring a similar cocktail mentioned above with bortezomib omitted.
Another trial known as ALGONQUIN is testing the combination of of belantamab mafodotin with pomalidomide and dexamethasone (PomDex) in relapsed/refractory patients who had received at least two lines of treatment, including lenalidomide and a proteasome inhibitor.
The drug has been the focus of 39 trials too date.